Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McDONALD, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by McDONALD, L.
(Chest. 1961;39:317-322.)
© 1961 American College of Chest Physicians

SUMMARY OF CURRENT THERAPY

The Rationale for the Treatment of Ischemic Heart Disease with Anticoagulants

LAWSON McDONALD M.D.1

1 Assistant Director, Institute of Cardiology, London.

Editors: Eliot Corday.

There is clear evidence of phasic hypercoagulability when the blood of patients with ischemic heart disease is studied in vitro . This is entirely in keeping with a variable hyperthrombotic state, and ischemic heart disease is marked clinically by episodes of thrombosis. With regard to anticoagulant therapy in the management of ischemic heart disease, it seems reasonable to assume that any measure which safely corrects hypercoagulability and returns blood coagulation to normal, should improve the prognosis.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1961 by the American College of Chest Physicians.